# Junta clínica — PT-pseudo_2b3ef1d3a505 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_2b3ef1d3a505",
  "pid": "PT-pseudo_2b3ef1d3a505",
  "task": 1,
  "psa": 4.2,
  "age": 67,
  "months": 2,
  "pirads": "5",
  "psad": 0.06,
  "psav": 0.66,
  "psap": 3.7,
  "vol": 69.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.81166416,
  "medhx": "COPD",
  "meds": "tiotropium, salbutamol PRN",
  "notes": "PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.",
  "pmhx": [
    "COPD"
  ],
  "allergies": [],
  "vitals": {
    "weight": "66 kg",
    "height": "185 cm",
    "bmi": "19.3",
    "bp": "113/72 mmHg",
    "hr": "74 bpm",
    "smoking": "Ex-smoker (30 pack-yr, quit 2015)",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "23 Jan 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review."
    },
    {
      "s": "History",
      "t": "A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent."
    }
  ],
  "occupation": "mechanical engineer",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Nephew",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Pulmonary function test — known COPD follow-up",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "31 units / week (heavy)",
  "exercise": "Light weight-training at home, 2x/week",
  "ipss": "IPSS score: 9/35 (moderate LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2b3ef1d3a505
Task: 1

Encounter: Urology - outpatient on 23 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.06 ng/mL²
  - PSA velocity: 0.66 ng/mL/yr
  - Prior PSA: 3.7 ng/mL
  - Prostate volume: 69.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81166416 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.

Vitals: weight 66 kg, height 185 cm, BMI 19.3, BP 113/72 mmHg, HR 74 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2015).

Chief complaint: Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review.

History: A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management.

Physical examination: DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: mechanical engineer; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 31 units / week (heavy); exercise Light weight-training at home, 2x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.35
  uncertainty  +/- 0.15 epistemic (95% band 0.05-0.65); among patients I cannot tell apart the outcome was 0.93 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 1 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 67 (2% of my signal; from age) · DRE = Nodus (10% of my signal; from dre_suspicious) · PSA = 4.2 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 69 mL (1% of my signal; from log_vol, vol) · PSA density = 0.06 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.81 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 67 · DRE = Nodus · PSA = 4.2 ng/mL · prostate volume = 69 mL · PSA density = 0.06 · PI-RADS = 5 · comorbidity = 1 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 48 men I have seen in this same situation (Positive prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 1.36: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."
  2. distance 1.61: PI-RADS 5, PSA 8.6, PSAD 0.202, age 68, DRE Nodus -> BIOPSY (clear). He wrote: "Patient reasonable to discuss curative treatment with (age 68, no very dramatic comorbidity, unfavorable intermediate risk disease). Considering he chose not curative tr…"
  3. distance 1.68: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"

PRECEDENT: DEFER (weighted vote 0.32 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · age = 67 · DRE = Nodus · PSA = 4.2 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · prostate volume = 69 mL · PSA density = 0.06
  not used   csPCa probability, comorbidity
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 67 · DRE = Nodus · PSA = 4.2 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · prostate volume = 69 mL · PSA density = 0.06 · comorbidity = 1 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using a risk-adapted pathway based on PI-RADS score, PSA density, and prior biopsy status. It states, "In a contemporary series of biopsies, the likelihood of finding a csPCa after follow-up biopsy after a diagnosis of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia (PIN) was only 6-8% - not significantly different from follow-up biopsies after a negative biopsy." This suggests that the decision depends on risk factors like PSA density and PI-RADS score.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I note that the guideline makes the PSA density threshold of 0.15 ng/mL/cc decisive in risk stratification, whereas EXPERT-STRUCTURED marked PSA density as 'not used'. The guideline suggests that a PSA density below 0.15 ng/mL/cc, combined with other factors, could lead to avoiding biopsy. The guideline requires the prior biopsy status to be established to determine the appropriate pathway. The guideline needs the documented prior grade of the prior biopsy to determine if a repeat biopsy is warranted.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at Positive the guideline suggests the decision depends on risk factors like PSA density and PI-RADS score.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the rising PSA velocity of 0.66 ng/mL/yr is a factor that must be considered in the risk assessment.
laboratory_results - the PSA density: the PSA density of 0.06 ng/mL/cc is a variable that the guideline uses to stratify risk.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on the documented grade of the prior biopsy and how the risk factors, particularly PSA density and PI-RADS, interact with the EAU guideline.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the mpMRI prose indicate whether the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> How does the rising PSA velocity of 0.66 ng/mL/yr factor into the risk assessment?
  previous_notes (get_previous_notes) -> What is the documented grade (Gleason/ISUP) of the prior biopsy, and is a surveillance protocol in place?
  laboratory_results (get_lab_results) -> What is the PSA density of 0.06 ng/mL/cc, and how does this stratify risk according to the guideline?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade of the prior biopsy?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Given the PSA density of 0.06 ng/mL/cc and PI-RADS 5, what is the recommended pathway according to the EAU guideline?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: PI-RADS 5 lesion in the right mid-peripheral zone. Prostate volume 69.0 mL. PSAD 0.06 ng/mL/mL. csPCa predicted probability 0.81166416.

psa_trend
PSA 0.8 (Jun 2023) rising to 4.2 (Jan 2025), steepest in the last year.

previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: not recorded
SURVEILLANCE: Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results.
TREATMENT: none recorded

laboratory_results
PSA 4.2 ng/mL (09 Dec 2024) rising to 4.2 ng/mL (09 Dec 2024), shape: single value.

WHAT I DID NOT OPEN
family-history anamnesis, because it was not requested by the plan and would not change the decision based on the other evidence.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 from the mpMRI report.
Rising PSA velocity of 0.66 ng/mL/yr from the PSA trend.

AGAINST sampling this patient now
PRIOR GRADE: not recorded from previous notes.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.20 ng/mL over 4 points spanning 19 months; velocity +1.58 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 6.5 ng/mL, conformal 95% band 1.9-22.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 4.2 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.36
  uncertainty  +/- 0.16 epistemic (95% band 0.06-0.67), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Nodus (5% of my signal; from dre_suspicious) · PSA = 4.2 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 69 mL (4% of my signal; from log_vol, vol) · PSA density = 0.06 (0% of my signal; from psad_calc) · comorbidity = 1 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.35  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.36  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-EXPERIENCE  DEFER, p(biopsy)=0.32  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.36 — carried by weighted panel.
PANEL ANSWER: NO BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          67                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Nodus                        E1:not E3:not cohort:not library:IMP E2:—            -> important
  psa          4.2 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          69 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.06                         E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.81                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  1 on the problem list        E1:IMP E3:not cohort:not library:— E2:—              -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: borderline.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes, laboratory_results) address the moderator's questions to the extent that they provide context but do not explicitly state the documented grade of the prior biopsy.

ALIGNMENT WITH THE PANEL
The retrieved evidence does not directly confirm or refute the PANEL-PROTOCOL's answer of NO BIOPSY, as the critical variable—the documented prior grade—remains unrecorded in the retrieved notes.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade of the prior biopsy? This question remains unanswered by the retrieved documents.

WHAT CARRIES WEIGHT, AND WHY
prior biopsy: Positive (noted) because the panel protocol weighted this as decisive, but the registrar's notes explicitly state "PRIOR GRADE: not recorded," which undermines the basis for the panel's decision.
psad: 0.06 (noted) as per the panel, but the EAU guideline suggests this variable is key for risk stratification, which is not fully resolved.
confidence: borderline, because the panel's decision rests on a missing piece of information that the registrar failed to retrieve.

MY SUGGESTION TO THE CHAIR
I suggest deferring the decision until the documented grade of the prior biopsy is obtained, as this is a critical variable required by the EAU guideline and is missing from the retrieved evidence.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: borderline)

67y/o, PSA 4.2, PI-RADS 5, prior positive biopsy with unrecorded grade. The PI-RADS 5 finding pulls toward biopsy, but the lack of prior grade documentation makes the decision difficult. Given the unchanged lesion status, deferring biopsy is chosen, with re-imaging in two years and a low threshold for future biopsy.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
